{"id":"NCT05052983","sponsor":"Galderma R&D","briefTitle":"A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis","officialTitle":"A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-24","primaryCompletion":"2023-09-11","completion":"2023-09-11","firstPosted":"2021-09-22","resultsPosted":"2024-10-08","lastUpdate":"2024-10-08"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Prurigo Nodularis"],"interventions":[{"type":"DRUG","name":"Nemolizumab","otherNames":["CD14152"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nemolizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the Long-term-Extension (LTE) study RD.06.SPR.202699 (NCT05052983). The secondary objective of this study is to assess the safety of nemolizumab compared to placebo over a 24-week period in participants with PN who previously responded to treatment in the LTE study.","primaryOutcome":{"measure":"Time From Baseline to Relapse Meeting At Least 1 of the Defined Criteria","timeFrame":"Baseline up to Week 24","effectByArm":[{"arm":"Nemolizumab","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":112.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","Austria","France","Germany","Poland","South Korea","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["COVID-19","Headache","Influenza","Nasopharyngitis","Sinusitis"]}}